FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors

Neuroscience Letters

Volumn 550, Issue , 2013, Pages 119-124

  Schroeder, Frederick A ^a   Chonde, Daniel B ^a   Riley, Misha M ^a   Moseley, Christian K ^a   Granda, Michael L ^a   Wilson, Colin M ^a   Wagner, Florence F ^b   Zhang, Yan Ling ^b   Gale, Jennifer ^b   Holson, Edward B ^b   Haggarty, Stephen J ^a   Hooker, Jacob M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Acetylation; Chromatin; Epigenetic; Metabolism; Necuroimaging; Rat

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; TACEDINALINE;

ACETYLATION; ANTERIOR CINGULATE; ARTICLE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE TRANSPORT; HIPPOCAMPUS; HISTONE ACETYLATION; HUMAN; IC 50; IN VITRO STUDY; INFERIOR COLLICULUS; MAXIMUM PLASMA CONCENTRATION; NEUROIMAGING; NONHUMAN; OLFACTORY NUCLEUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PYRIFORM CORTEX; THALAMUS NUCLEUS; WESTERN BLOTTING;

ACETYLATION; CHROMATIN; EPIGENETIC; METABOLISM; NECUROIMAGING; RAT;

ANIMALS; BRAIN; FLUORODEOXYGLUCOSE F18; GLUCOSE; HISTONE DEACETYLASE INHIBITORS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEUROIMAGING; PHENYLENEDIAMINES; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 84881376767     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.016     Document Type: Article

References (32)

1. Akbarian S., Nestler E.J. Epigenetic mechanisms in psychiatry. Neuropsychopharmacology 2013, 38:1-2.
2. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2010, 6:238-243.
3. Covington H.E., Maze I.Q.C., LaPlant V.F., Vialou Y.N., Ohnishi O., Berton D.M., Fass W., Renthal A.J., Rush E.Y., Wu S., Ghose V., Krishnan S.J., Russo C., Tamminga S.J., Haggarty E.J., Nestler Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 2009, 29:11451-11460.
4. Diyabalanage H.V., Granda M.L., Hooker J.M. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 2013, 329:1-8.
5. Dunlop B.W., Binder E.B., Cubells J.F., Goodman M.M., Kelley M.E., Kinkead B., Kutner M., Nemeroff C.B., Newport D.J., Owens M.J., Pace T.W., Ritchie J.C., Rivera V.A., Westen D., Craighead W.E., Mayberg H.S. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials 2012, 13:106.
6. Endepols H., Sommer S., Backes H., Wiedermann D., Graf R., Hauber W. Effort-based decision making in the rat: an [18F]fluorodeoxyglucose micro positron emission tomography study. J. Neurosci. 2010, 30:9708-9714.
7. Fass D.M., Kemp M.M., Schroeder F.A., Wagner F.F., Wang Q., Holson E.B. Histone acetylation and deacetylation. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2012, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. Second Edition. R.A. Meyers (Ed.).
8. Fass D.M., Reis S.A., Ghosh B., Hennig K.M., Joseph N.F., Zhao W.N., Nieland T.J.F., Guan J.S., Kuhnle C.E.G., Tang W.P., Barker D.D., Mazitschek R., Schreiber S.L., Tsai L.H., Haggarty S.J. Crebinostat A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology 2013, 64:81-96.
9. Fass D.M., Schroeder F.A., Perlis R.H., Haggarty S.J. Epigenetic mechanisms in mood disorders: targeting neuroplasticity. Neuroscience 2013, Epub ahead of print.
10. Febo M., Akbarian S., Schroeder F.A., Ferris C.F. Cocaine-induced metabolic activation in cortico-limbic circuitry is increased after exposure to the histone deacetylase inhibitor, sodium butyrate. Neurosci. Lett. 2009, 465:267-271.
11. Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
12. Guan J.S., Haggarty S.J., Giacometti E., Dannenberg J.H., Joseph N., Gao J., Nieland T.J., Zhou Y., Wang X., Mazitschek R., Bradner J.E., DePinho R.A., Jaenisch R., Tsai L.H. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
13. E. Holson, F.F. Wagner, M. Weiwer, Inhibitors of histone deacetylases. WO2012149540, USA, 2012.
14. Hooker J.M., Patel V., Kothari S., Schiffer W.K. Metabolic changes in the rodent brain after acute administration of salvinorin A. Mol. Imaging Biol. 2009, 11:137-143.
15. Jang D.P., Lee S.H., Park C.W., Lee S.Y., Kim Y.B., Cho Z.H. Effects of fluoxetine on the rat brain in the forced swimming test: a [F-18]FDG micro-PET imaging study. Neurosci. Lett. 2009, 451:60-64.
16. Kennedy P.J., Feng J., Robison A.J., Maze I., Badimon A., Mouzon E., Chaudhury D., Damez-Werno D.M., Haggarty S.J., Han M.H., Bassel-Duby R., Olson E.N., Nestler E.J. Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. Nat. Neurosci. 2013, 16:434-440.
17. Kim W.Y., Kim S., Kim J.H. Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity. Neurosci. Lett. 2008, 432:54-57.
18. Klein J., Hadar R., Gotz T., Manner A., Eberhardt C., Baldassarri J., Schmidt T.T., Kupsch A., Heinz A., Morgenstern R., Schneider M., Weiner I., Winter C. Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in two rat models of schizophrenia. Brain Stimul. 2013, 6(4):490-499. Epub 2012, Oct 8.
19. Malvaez M., McQuown S.C., Rogge G.A., Astarabadi M., Jacques V., Carreiro S., Rusche J.R., Wood M.A. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2647-2652.
20. McNay E.C., Ong C.T., McCrimmon R.J., Cresswell J., Bogan J.S., Sherwin R.S. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem. 2010, 93:546-553.
21. Methot J.L., Chakravarty P.K., Chenard M., Close J., Cruz J.C., Dahlberg W.K., Fleming J., Hamblett C.L., Hamill J.E., Harrington P., Harsch A., Heidebrecht R., Hughes B., Jung J., Kenific C.M., Kral A.M., Meinke P.T., Middleton R.E., Ozerova N., Sloman D.L., Stanton M.G., Szewczak A.A., Tyagarajan S., Witter D.J., Secrist J.P., Miller T.A. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett. 2008, 18:973-978.
22. Moradei O.M., Mallais T.C., Frechette S., Paquin I., Tessier P.E., Leit S.M., Fournel M., Bonfils C., Trachy-Bourget M.C., Liu J., Yan T.P., Lu A.H., Rahil J., Wang J., Lefebvre S., Li Z., Vaisburg A.F., Besterman J.M. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem. 2007, 50:5543-5546.
23. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., Diehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., de Leon M.J. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 2008, 49:390-398.
24. Paxinos G.W.C. The Rat Brain in Steretaxic Coordinates 1998, Academic Press, Inc., San Diego, CA, USA. 4th ed.
25. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 2007, 62:55-64.
26. Schroeder F.A., Penta K.L., Matevossian A., Jones S.R., Konradi C., Tapper A.R., Akbarian S. Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviors. Neuropsychopharmacology 2008, 33:2981-2992.
27. Skelin I., Sato H., Kovacevic T., Diksic M. Chronic therapy with citalopram decreases regional cerebral glucose utilization in OBX, and not sham-operated, rats: an autoradiographic study. Psychopharmacology (Berl.) 2009, 207:315-323.
28. Sullivan R.M. Hemispheric asymmetry in stress processing in rat prefrontal cortex and the role of mesocortical dopamine. Stress 2004, 7:131-143.
29. Wacker D.W., Engelmann M., Tobin V.A., Meddle S.L., Ludwig M. Vasopressin and social odor processing in the olfactory bulb and anterior olfactory nucleus. Ann. N.Y. Acad. Sci. 2011, 1220:106-116.
30. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
31. Williams L.M., Rush A.J., Koslow S.H., Wisniewski S.R., Cooper N.J., Nemeroff C.B., Schatzberg A.F., Gordon E. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 2011, 12:4.
32. Yeh H.H., Tian M., Hinz R., Young D., Shavrin A., Mukhapadhyay U., Flores L.G., Balatoni J., Soghomonyan S., Jeong H.J., Pal A., Uthamanthil R., Jackson J.N., Nishii R., Mizuma H., Onoe H., Kagawa S., Higashi T., Fukumitsu N., Alauddin M., Tong W., Herholz K., Gelovani J.G. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with (1)(8)F-FAHA. Neuroimage 2013, 64:630-639.